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This study aimed to investigate phenotype of RP105(−) B cell subsets in patients with systemic lupus erythematosus (SLE). Flow
cytometry was used for phenotyping RP105-negaive B cell subsets. Based on CD19, RP105, and CD138 expression, RP105(−)
B cells consist of at least 5 subsets of late B cells, including CD19(+)RP105(int), CD19(+) RP105(−), CD19(low) RP105(−)
CD138(−), CD19(low) RP105(−)CD138(int), and CD19(low) RP105(−) CD138(++) B cells. Especially, CD19(+)RP105(int)
and CD19(low) RP105(−)CD138(int) B cells are signiﬁcantly larger than other RP105(−) B cell subsets in SLE. By comparison
of RP105(−) B cell subsets between patients with SLE and normal subjects, these subsets were detectable even in normal subjects,
but the percentages of RP105(−) B cell subsets were signiﬁcantly larger in SLE. The phenotypic analysis of RP105(−)Bc e l ls u b s e t s
suggests dysregulation of later B cell subsets in SLE and may provide new insights into understanding regulation of B cells in
human SLE.
1.Introduction
Systemic lupus erythematosus (SLE) is a typical systemic
autoimmune disease characterized by production of vari-
ous autoantibodies including anti-double-strand (ds) DNA
antibodies from B cells [1–4]. Although the pathogenesis
of SLE is not fully clariﬁed, autoantibody-producing B cells
play a pivotal role in developing autoimmunity in SLE [3,
5]. Therefore, understanding of human B cell biology in
autoimmune diseases is an essential issue.
RP105 (CD180) is one of the homologues of Toll-like
receptors (TLRs). RP105 expresses on mature B cells, macro-
phages, and dendritic cells (DCs) [6]. It has been reported
thatRP105isassociatedwithactivationofBcellsinmiceand
humans [7, 8]. RP105 also facilitates macrophage activation
by mycobacterium tuberculosis lipoproteins through TLR2
[9]. However, we and other investigators have reported
that RP105 negatively regulates the signal of TLR4 in DCs
[10, 11]. Although the function of RP105 is still controversial
and undeﬁned, RP105 may aﬀect activation and function of
B cells in immune systems.
We have previously reported that enlarged population of
RP105-lacking [RP105(−)] B cells in peripheral blood (PB)
is an outstanding feature in patients with active SLE [12, 13].
Although RP105(−) B cells may be assigned to be subsets of
activated late B cells with producing immunoglobulins (Igs)
and anti-dsDNA antibodies [14], precise phenotype has not
been examined yet.
Late B cells, including plasmablasts and plasma cells, play
critical roles in humoral immune response and autoimmune
diseases [15]. Comparison of the B cell subsets in healthy
subjects with SLE patients could lead to relevant observa-
tions. The phenotypic analysis of subsets of RP105(−)Bc e l l s
is helpful to understand the dysregulation of late B cells in
SLE.
2.MaterialsandMethods
2.1. Patients and Agents. Patients with active SLE (n = 15)
(14 women and 1 man, mean ± SD age: 41.2 ± 10.5 years)
were enrolled in this study, who fulﬁlled at least 4 of the 112 Clinical and Developmental Immunology
classiﬁcation criteria for SLE as deﬁned by the American
College of Rheumatology [16] and as updated in 1997 [17].
None of the active SLE patients was receiving immuno-
suppressive drugs at the time of examination. Age-matched
7 healthy volunteers joined as controls (6 women and 1 man,
38.2 ± 9.1 years). Written informed consent was obtained
from all subjects prior to sample acquisition. The study
protocol was approved by the Ethics Committees of Saga
University, and the subjects’ written consent was obtained
according to the Declaration of Helsinki at the General
Assembly in October 2008.
The following monoclonal antibodies (mAbs) were used
in our studies ﬂuorescein isothiocyanate- (FITC-) conjugat-
ed, phycoerythrin- (PE-) conjugated, or allophycocyanin-
(APC-) conjugated antihuman CD19, FITC-conjugated or
PE-conjugated antihuman RP105, FITC- or PE-conjugated
anti-CD19, anti-CD20, anti-CD22, anti-CD24, anti-CD27,
anti-CD28, anti-CD30, anti-CD31, anti-CD38, anti-CD40,
anti-CD62L, anti-CD70, anti-CD72, anti-CD77, anti-
CD79b, anti-CD80, anti-CD86, anti-CD95, anti-CD97,
anti-CD126, anti-CD138, anti-CD147, anti-CD164, anti-
CD200, anti-CD209, anti-CD267, anti-CD275, anti-CD279,
anti-CCR7, anti-CXCR5 (CD185), anti-HLA-DR, anti-IgG,
anti-IgM, anti-IgD, anto-TLR5, anti-TLR6, PE-conjugat-
ed anti-CD10, anti-CD21, anti-CD23, anti-CD25, anti-
CD27, anti-CD28, anti-CD45RO, anti-CD69, anti-CD77,
anti-CD122, anti-CD125, anti-CD132, anti-CD150, anti-
CD152, anti-CD184 (CXCR4), anti-CCR2, anti-CCR10,
anti-CX40, and anti-TLR2 were purchased from BD Bio-
science (San Jose, CA, USA). The mAbs to human BCMA (B
cell maturation antigen) (Vicky-1, rat IgG1), BAFF-R (B cell
activating factor receptor) (11C1, mouse IgG1), and TACI
(transmembrane activator and calcium modulator ligand
interactor; CD267) (1A1, rat IgG2a) were obtained from
ALEXIS Biochemical (Piscataway, NJ, USA). FITC- or PE-
conjugated isotype-matched control mAbs were purchased
from BD Bioscience. PerCP- (Peridinin chlorophyll protein-)
conjugated CD138 was also obtained from BD Bioscience.
2.2. Flow Cytometric Analysis. Heparinized peripheral ve-
nous blood was obtained from patients with SLE. PB mon-
onuclear cells (PBMCs) were separated immediately by cen-
trifugation over Ficoll-Hypaque (Pharmacia Biotech, Upp-
sala, Sweden). PBMCs were washed twice and resuspended
at 1 × 106 cells/mL in staining buﬀer.
Direct immunoﬂuorescence was carried out with PE-
or FITC-conjugated antibodies against surface antigens and
stained with FITC- or PE-conjugated anti-RP105, PerCP-
conjugated anti-CD138, and APC-conjugated anti-CD19
mAbs. Irrelevant isotype-matched control antibodies were
used to determine background ﬂuorescence. These samples
were analyzed with the saved setting of gate. More than
500000 viable, antibody-labeled cells were identiﬁed accord-
ing to their forward and side scattering, electronically gated,
andanalyzedonaF A CScaliburﬂowcytometer(BectonDick-
inson). Results were expressed as percent of positive cells or
mean ﬂuorescence intensity (MFI) using WINMDI software
(http://facs.scripps.edu/software.html). The percentages of
subsets of RP105(−) B cells (RP105(−) CD19(+) subset
cells/CD19(+) cells%) were calculated.
2.3. Statistical Analysis. Statistical analysis was performed
with the Mann-Whitney U test, the Wilcoxon signed rank
test, or Student’s t-test using SPSS software (SPSS Japan Inc.,
Tokyo, Japan); statistical signiﬁcance was considered with a
P<0.05.
3. Results
3.1. RP105-Negative B Cells Consist of 5 Subsets of B Cells.
In SLE patients, there is a large population of RP105(−)B
cells [12]. Figure 1(a) shows a representative FACS proﬁle
of CD19 and RP105 expression on PBMCs from a patient
with SLE and a normal subject. As reported in the previous
studies [12, 13], a signiﬁcant population of CD19(+) B cells
fromSLEpatientslackedRP105.Inthisstudy,inconjunction
with RP105, we used the B cell marker CD19 and plasma cell
marker CD138 in an attempt to subdivide RP105(−)Bc e l l s
further.
We identiﬁed 4 populations of B cells in the panel of
CD19 and RP105. The populations were CD19(+)RP105(+)
B cells (subset 0) and three RP105(−) B cell subpopulations,
CD19(+)RP105(int; intermediate) (subset 1), CD19(+)
RP105(−) (subset 2), and CD19(low)RP105(−)Bc e l l s
(presubset). The population of CD19(low)RP105(−)Bc e l l s
(presubset) was (subset 3), CD19(low)RP105(−)CD138(int)
(subset 4), and CD19(low)RP105(−)CD138(++) (subset 5)
B cells according to CD138 expression levels after gating
presubset (Figure 1(b)). Collectively, we identiﬁed at least 5
subsets of RP105(−) or (low) B cells.
The percentages of subsets in PB of each patient and
normal subject were shown in Figure 1(c). Among these
subsets, the populations of subset 1 (10.4 ± 4.4%) and 3
(7.1 ± 5.8%) B cells were larger than other subsets (subset
2; 5.0 ± 3.5%, subset 4; 3.8 ± 4.2%, subset 5; 1.6 ± 1.7%).
All RP105-negative B cell subsets of SLE patients were
signiﬁcantly increased compared with normal subjects.
3.2. Phenotype of RP105-Negative B Cell Subsets in SLE.
In order to characterize these subsets, we analyzed various
antigens on B cells (Figures 2 and 3). Subset 0, 1, and 2 B
cells were positive for CD20, but in subset 3, 4, and 5 B cells,
CD20 expression decreased. Although subset 0, 1, and 2 B
cells expressed CD21, CD22, and CD24, subset 3, 4, and 5
B cells lost CD22 completely, and expression levels of CD21
and CD24 were lower compared to subset 0, 1, and 2 B cells.
CD23 expression was low only in subset 4 and 5 B cells.
Ontheotherhand,CD38andCD27expressionswerethe
lowestonsubset0Bcells.ThelevelsofCD38andCD27grad-
ually increased from subset 1 to subset 4 and 5 B cells. While
subset 0, 1, and 2 B cells expressed surface IgD and IgM,
subset3,4,and5BcellshadlowerlevelsofsurfaceIgs.Allthe
subsets of RP105(−) B cells expressed HLA-DR. However,
the levels of HLA-DR gradually decreased. Low expression
of CD25 was detectable in subset 0, 1, 2, and 3 B cells.
CXCR5 (CD185), a homing receptor, presented in subset
0, 1, and 2 B cells, but it disappeared in the subset 3, 4, andClinical and Developmental Immunology 3
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Figure 1: Subsets of RP105(−) B cells. (a) Representative ﬂow cytometric proﬁles of RP105 expression on CD19(+) B cells from an active
SLE patient and a normal subject. The population was subdivide (1) subset 1; CD19(+)RP105(int), (2)subset 2; CD19(+)RP105(−), and (3)
presubset; CD19(low)RP105(−). (b) CD138 levels after gating CD19(low)RP105(−) presubset. The presubset cells were further subdivided
into 3 subpopulations, subset 3; CD138(−), subset 4; CD138(int) and subset 5; CD138(++). (c) The percentages of subsets in PB of each
patient and normal subject. ∗P<0.05,
∗∗P<0.05.
5 B cells. The expression of CXCR4 (CD184) was the highest
in subset 0 B cells but was lost in subset 4 and 5 B cells.
More interestingly, of BAFF receptors, BAFF-R expres-
sion was higher in subset 0, 1, and 2 B cells, but BCMA
expression was conversely higher in subset 3, 4, and 5 B cells.
From subset 0 to subset 2 B cells, CD72, CD79b, and
CD200 expressions were found, but those were lower on
subset 3, 4, and 5 B cells. CD86, CD95, CD97, and CD126
were positive on subset 3, 4, and 5 cells. CD1a, CD1b, CD10,
CD40, CD77, and CD80 were low or negative in all subsets.
CD31, CD49d, and CD45RA were constantly positive on all
subsets (data not shown).
We investigated and summarized the phenotype of
RP105(−) B cell subsets in patients with active SLE.
RP105(−) B cells consist of at least 5 subsets of late B
cells, including CD19(+)RP105(int), CD19(+) RP105(−),
CD19(low)RP105(−)CD138(−), CD19(low) RP105(−)CD138
(int), and CD19(low)RP105(−)CD138(++) B cells. The phe-
notypic analysis of RP105(−) B cells suggests mature pheno-
type of these RP105(−) B cells, CD20(low or lost) CD22(low
or lost) CD27(high) CXCR5(low or lost).
3.3. Phenotype of RP105-Negative B Cell Subsets in Normal
Subjects. We analyzed whether our ﬁnding of subsets of
RP105(−) B cells is valid in healthy subjects. Although
circulating RP105(−) B cells are very rare in healthy subjects,
subsets of RP105(−)Bc e l l sw e r ei d e n t i ﬁ e d .T h e r e f o r e ,
comparisonoftheidentiﬁedBcellsubsetsinhealthysubjects
with SLE patients could lead to relevant observations.
Virtually, patterns of phenotype of RP105(−)Bc e l l s
from normal subjects seemed similar to those from SLE
patients. However, the expression levels of several antigens
were signiﬁcantly diﬀerent between SLE patients and normal
subjects (Figure 4). In subset 3, 4, and 5, levels of CD38 and
HLA-DR of SLE patients were signiﬁcantly higher than those
of normal subjects (P<0.05). On the other hand, in subset
4 and 5, levelsof CD95 were lower in SLE patients compared
with normal subjects (P<0.05).
4. Discussion
RP105 (CD180) is mainly expressed on mature B cells and
regulates B cell function in humans and mice [6]. Enlarged
population of RP105(−) B cells was remarkable in active
patients with SLE [12]. In the past studies we suggested that
RP105(−) B cells are activated and well-diﬀerentiated B cells.
However, precise phenotype of RP105(−)Bc e l l sh a sn o t
been elucidated. We described here phenotype of human late4 Clinical and Developmental Immunology
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Figure 2: Flow cytometric analysis of various antigens on and in B cell subsets from a patient with SLE. Positive cell ratio or MFI (mean
ﬂuorescence intensity) was shown in ﬂow cytometric proﬁles.6 Clinical and Developmental Immunology
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Figure 3: Expressions of important B cell markers (MFI) on RP105(−) B cells (subset 1–5) and RP105(+) B cells (subset 0). The levels of
CD19, CD20, and CD24 were signiﬁcantly lower in subset 3, 4, and 5 B cells compared to subset 0, 1, and 2 B cells (P<0.05). CD27 and
CXCR5 expression was signiﬁcantly diﬀerent: (P<0.05 subset 0 versus 1, subset 1 versus 2, subset 2 versus 3, subset 3 versus 4, and subset 4
versus 5).
B cells more precisely using markers of CD19, RP105, and
CD138.
We identiﬁed 5 subpopulations of RP105(−)Bc e l l sw i t h
diﬀerentphenotypethatarecategorizedasfollows:subset(1)
CD19(+)RP105(int),(2)CD19(+)RP105(−),(3)CD19(low)
RP105(−)CD138(−), (4) CD19(low)RP105(−)CD138(int),
and (5) CD19(low)RP105(−)CD138(++) B cells. Each sub-
setofRP105(−)BcellsshoweddiﬀerentphenotypeofBcells.
IgD and CD38 were classically used to subdivide PB
B cells into four quadrants, IgD(+)CD38(−)n a ¨ ıve B cells
(Bm1andBm2),IgD(+)CD38(+)Pre-GCBcells(Bm2’aand
Bm2’b), IgD(−)CD38(+) GC B cells (Bm3 and Bm4), and
IgD(−)CD38(−)m e m o r yBc e l l s( B m 5 )[ 18]. According to
this classiﬁcation system, subset 3, 4, and 5 of RP105(−)
B cells, expressing CD38 and lacking surface IgD, may be
tentatively considered to belong to GC B cells. Although
GC B cells are CD10(+), CD20(++), and CD27(−), the
RP105(−) B cells lost CD10 and CD20, but express CD27.
Therefore, several subsets of RP105(−)Bc e l l sd on o t
correspond with classically categorized GC type B cells.
CD27 expression is commonly used as an exclusive
marker for human memory B cells [18]. Although memoryClinical and Developmental Immunology 7
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Figure 4: Comparison of surface expression of various antigens
with signiﬁcant diﬀerence of mean of MFI on RP105(−)Bc e l l
subsets between SLE patients and normal subjects.
B cells express CD27 and lack IgD and CD38, 5 subsets
of RP105(−) B cells clearly expressed CD38. Accordingly,
RP105(−) B cells are not memory type B cells. Several
previous reports have shown that CD27-bright plasma cells
increasehighly in PBMC from patients with active SLE and
that the frequency is useful in evaluating disease activity with
a signiﬁcant correlation with SLEDAI and autoantibodies
[19, 20]. We presented CD27 expression of RP105-negative
B cell subsets in Figures 2 and 3. CD27 expression was
g r a d u a l l yi n c r e a s e df r o ms u b s e t0t os u b s e t5 .I th a s
been reported that CD27 expression is upregulated during
Bc e l l sd i ﬀerentiation into plasma cells [21]. Therefore,
higher expression of CD27 on B cells is also a marker of
diﬀerentiation towards plasma cells [21]. Based on CD20,
CD27, and CD38 expressions, RP105(−) B cells correspond
neither to germinal center B cells nor memory B cells.
It is reported that in vitro human activated B cells and
plasmablasts/plasma cells express CD19, whose levels, how-
ever, are lower on plasmablasts and plasma cells compared to
activatedBcells[22].Actually,inthisstudy,CD19expression
was lower in subset 3, 4, and 5 B cells.
Regarding homing receptors, diﬀerentiated plasma cells
arecharacterizedbyadisappearanceofCXCR5,aprogressive
reduction in CXCR4 [22]. From subset 0 to subset 5 B cells,
CXCR5 and CXCR4 levels became decreased. The expression
levels of these molecules also suggested that RP105(−)Bc e l l
subsets may belong to the cells during the process towards
plasma cell formation.
RP105(−)BcellshaveabundantintracellularIgs[12]but
lost surface Igs. Therefore, subset 3, 4, and 5 B cells may be
assigned as to be plasmablasts or plasma cells, preparing to
secret Igs. However, due to lacking CD138, subset 3 B cells
may be assigned as plasmablasts not as plasma cells. On the
other hand, subset 4 B cells may be assigned as preplasma
cells due to intermediate CD138 expression and subset 5 B
cells as PB plasma cells with bright CD138.
Collectively, each subset represents the step of B cell
diﬀerentiation towards plasma cells. However, to conﬁrm
each steps comparison between PB and bone marrow plasma
cells is required. Further analysis of in vitro culture of B
cells that develop and diﬀerentiate into plasma cells with
morphological change, functional studies, and expression of
transcription factors is also important. In our results, we
present the existence of increased various late B cell subsets
in SLE patients.
We performed phenotype analysis in healthy subjects.
The results were shown in Figures 1 and 4. Although
circulating RP105(−) B cells are very rare, we found the
subsets of RP105(−) B cells even in healthy subjects. The
comparisonoftheidentiﬁedBcellsubsetsinhealthysubjects
with SLE patients showed that, virtually, phenotype of
RP105(−)Bc e l l sf r o mn o r m a ls u b j e c t ss e e m e ds i m i l a rt o
those from SLE patients. Interestingly, the expression levels
of several antigens were diﬀerent between SLE and normal
subjects. However, the importance of the expression levels
of antigens for pathophysiology in SLE is not unclear in
this study. Therefore, further analysis of the antigens of
RP105(−)subsetsfoundinSLEpatientswithvariousactivity
and other systemic rheumatic diseases should be required.
Recently, it has been reported that increased circulating
CD138(int) B cells, producing autoantibodies, are related
to autoimmunity in MRL/lpr lupus mice [15]. RP105(−)
B cells showed similar phenotype with CD138(int) B cells:
(1) intermediate expression of CD138, (2) larger cell size
and increased granularity [12], (3) cytoplasmic Ig and IgM
expression. Thus, CD19(low)RP105(−)CD138(int) B cells
may be the human counterparts of CD138(int) B cells in
mice. These results suggest possible similar mechanisms in
dysregulation of B cells in human and murine autoimmune
diseases.
Further studies will be required to determine mech-
anisms of appearing, diﬀerentiation, and proliferation of
RP105(−) B cell in human SLE. It is possible that inappro-
priate enlarged population of various subsets of RP105(−)B
cells in PB is greatly related to pathophysiology in SLE.
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